Equity Profile

IMNM

Immunome, Inc.

Health CareBiotechnology$2.1B

Nov4Fri

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Immunome, Inc. is a biotechnology company focused on developing innovative therapies for cancer and other diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to scale and succeed in a competitive market.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

IMNM Q2-2026 Earnings Preview

Context

Company Snapshot

Immunome, Inc. is a biotechnology company focused on developing innovative therapies for cancer and other diseases. Operating in the Health Care sector, its work is crucial as it aims to harness the immune system to fight diseases, a theme that is increasingly important in modern medicine.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-68.16%

Avg Stock Reaction

-1.95%

Last Quarter Recap

In Q1-2026, Immunome reported an EPS of -$0.48, which was better than the expected -$0.60, showing a positive surprise. However, the stock fell by 1.35% the following day, indicating market skepticism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of the earnings report, especially given the company's mixed performance in previous quarters. There are no analyst estimates available, which adds uncertainty.

Bull Case

If Immunome can demonstrate improved financial metrics and a clearer path to revenue growth, it could regain investor confidence and see a positive stock reaction.

Bear Case

On the other hand, continued losses and lack of revenue could lead to further declines in stock price, especially if the company fails to meet even modest expectations.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for this quarter?

Given the company's history of EPS surprises, this number will be critical in determining market sentiment.

What is the outlook for revenue growth?

Investors need clarity on how the company plans to generate revenue moving forward, especially after previous disappointing results.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Immunome to surprise on the upside given recent operational improvements not yet reflected in analyst estimates.

Supporting Evidence

The options market is pricing a significant move, indicating expectations for a surprise.

Immunome's recent operational changes could lead to better-than-expected results despite historical performance.

Key Risk

If the EPS comes in better than -$0.40, it could challenge the current negative sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for improved financial performance against a backdrop of previous losses and uncertainty.

Bull Confirmed If

A positive EPS surprise of at least -$0.40 would confirm the bull case.

Bear Confirmed If

An EPS worse than -$0.60 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±44.3%

Historical Avg

±3.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±44.3% while IMNM has averaged ±3.8% over the last 8 prints — setup is pricing rich.

Detail

30d HV

54.2%

Calls (11K)P/C Ratio: 5.31Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Immunome beats expectations, history suggests the stock could rise by an average of 0.5%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline of around 3.4%, reflecting ongoing concerns about the company's financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new therapies in the pipeline.
2Details on partnerships or collaborations that could drive revenue.
3Management's commentary on cost management and operational efficiency.
4Insights into market conditions affecting the biotechnology sector.
5Any changes to the company's long-term strategy.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Cirrus Logic, Inc.

Company Snapshot

Immunome, Inc. is a biotechnology company focused on developing innovative therapies for cancer and other diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to scale and succeed in a competitive market.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

IMNM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-68.16%

Avg Stock Reaction

-1.95%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of the earnings report, especially given the company's mixed performance in previous quarters. There are no analyst estimates available, which adds uncertainty.

Bull Case

If Immunome can demonstrate improved financial metrics and a clearer path to revenue growth, it could regain investor confidence and see a positive stock reaction.

Bear Case

On the other hand, continued losses and lack of revenue could lead to further declines in stock price, especially if the company fails to meet even modest expectations.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for this quarter?

Given the company's history of EPS surprises, this number will be critical in determining market sentiment.

What is the outlook for revenue growth?

Investors need clarity on how the company plans to generate revenue moving forward, especially after previous disappointing results.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Immunome to surprise on the upside given recent operational improvements not yet reflected in analyst estimates.

Supporting Evidence

The options market is pricing a significant move, indicating expectations for a surprise.

Immunome's recent operational changes could lead to better-than-expected results despite historical performance.

Key Risk

If the EPS comes in better than -$0.40, it could challenge the current negative sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for improved financial performance against a backdrop of previous losses and uncertainty.

Bull Confirmed If

A positive EPS surprise of at least -$0.40 would confirm the bull case.

Bear Confirmed If

An EPS worse than -$0.60 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±44.3%

Historical Avg

±3.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±44.3% while IMNM has averaged ±3.8% over the last 8 prints — setup is pricing rich.

Detail

30d HV

54.2%

Calls (11K)P/C Ratio: 5.31Puts (100)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Immunome beats expectations, history suggests the stock could rise by an average of 0.5%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline of around 3.4%, reflecting ongoing concerns about the company's financial health.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new therapies in the pipeline.
2Details on partnerships or collaborations that could drive revenue.
3Management's commentary on cost management and operational efficiency.
4Insights into market conditions affecting the biotechnology sector.
5Any changes to the company's long-term strategy.